JARDIANCE® protects by reducing risk for adult patients with1:
CV disease
accounts for 50%
of deaths in patients with
T2D globally, and as
many as 50% of patients
may develop HF3,4
Metabolic
94% of patients with
T2D have 21 cardio-renal
or metabolic condition?
Chronic kidney
disease
disease
Reduced risk of CV death or
kidney disease progression*2